Insider Selling: X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Sells $210,615.84 in Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Chairman Adam Craig sold 47,436 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total value of $210,615.84. Following the completion of the sale, the chairman directly owned 328,651 shares of the company’s stock, valued at $1,459,210.44. The trade was a 12.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

X4 Pharmaceuticals Price Performance

XFOR opened at $4.22 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.30 and a quick ratio of 9.98. The company has a market capitalization of $418.41 million, a price-to-earnings ratio of -3.52 and a beta of 0.37. The firm’s fifty day moving average price is $4.05 and its two-hundred day moving average price is $3.96. X4 Pharmaceuticals, Inc. has a 1 year low of $2.45 and a 1 year high of $4.83.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its earnings results on Friday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.05. The firm had revenue of $8.81 million during the quarter, compared to analyst estimates of $2.42 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. As a group, analysts anticipate that X4 Pharmaceuticals, Inc. will post -0.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Wells Fargo & Company began coverage on shares of X4 Pharmaceuticals in a research report on Friday, July 10th. They issued an “overweight” rating and a $11.00 price objective for the company. Leerink Partners initiated coverage on shares of X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 target price on the stock. Finally, Weiss Ratings downgraded X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, X4 Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $11.25.

Hedge Funds Weigh In On X4 Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Indivisible Partners bought a new position in X4 Pharmaceuticals during the fourth quarter valued at about $40,000. Rhumbline Advisers raised its position in X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after acquiring an additional 9,690 shares during the period. SummitTX Capital L.P. bought a new stake in X4 Pharmaceuticals in the first quarter worth about $46,000. Pettinga Financial Advisors LLC purchased a new position in X4 Pharmaceuticals in the second quarter valued at about $47,000. Finally, Two Sigma Investments LP purchased a new position in X4 Pharmaceuticals in the third quarter valued at about $47,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.